Acceleration Robotics Launch ROBOTCORE™ to Speed-up ROS 2 Robots
16.6.2022 08:00:00 EEST | Business Wire | Press release
Acceleration Robotics S.L., a robotics semiconductor startup based in the Basque Country and focused on designing customized brains for robots to hasten their response time via FPGAs and GPUs released ROBOTCORE ™, a hardware acceleration framework for the Robot Operating System (ROS), the standard in robotics. Delivering semiconductor building blocks for robots, the company creates custom compute architectures for high performance robots through hardware acceleration while remaining robot and accelerator-agnostic (supporting popular FPGAs and GPUs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005050/en/
ROBOTCORE™ helps build faster compute architectures for robots, or robot cores, that makes robots faster, more deterministic and power-efficient. It provides a development experience for creating robot hardware accelerators similar to the standard ROS development flow. (Photo: Acceleration Robotics)
ROBOTCORE™ allows robotic engineers to create ROS and ROS 2 API-compatible Intellectual Property (IP) cores that increase the robot's performance, including latency and throughput. These “ robot cores” make robots faster, more deterministic and power-efficient. ROBOTCORE™ launches with support for more than 10 development boards, including the most popular hardware acceleration solutions to build robots with ROS.
The framework builds on top of proven open-source software in robotics, such as ROS 2, so that roboticists don't spend time redeveloping what already works and focus instead on delivering higher performance robotic applications. While providing a vendor-agnostic ROS-centric development flow, ROBOTCORE™ solves customer design challenges in robotic areas including sensing, perception, mapping, localization, motion control, low-level control or actuation, with speedups surpassing 500x modern processors.
“Robots are networks of networks, with sensors passing data to compute technologies and actuators. These networks can be understood as the nervous system of the robot. Like with the human nervous system, low latency and real-time information is fundamental for the robot to behave coherently. Faster robots (or with more dexterity) require faster computations. Hardware acceleration with ROBOTCORE™ empowers exactly this. With ROS being the common language roboticists use to build “robot brains”, ROBOTCORE™ extends ROS and deals with GPU and FPGA vendor-proprietary libraries, empowering hardware acceleration across silicon vendors”. – Víctor Mayoral-Vilches, Acceleration Robotics, Founder.
Additional resources
- ROBOTCORE ™ performance benchmarks
- Sign up for Hardware Acceleration News in Robotics
- Join the ROS 2 Hardware Acceleration Working Group
About Acceleration Robotics
Acceleration Robotics is a firm focused on designing customized brains for robots to hasten their response time. Founded by top robotic experts to deliver semiconductor building blocks for robots, the company leverages GPUs and FPGAs to create custom hardware that speeds up a robot's operation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005050/en/
Contact information
Víctor Mayoral-Vilches
(+34) 616151561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom